PD L1 is a protein known to reduce an immune cell's anti-cancer activity, and nivolumab works by blocking the receptor where PD L1 could bind to an immune cell, so preserving its anti-cancer activity.

Adjuvant therapy with nivolumab (Opdivo ... Plimack said, “whereas PD-L1 asks the question will adjuvant treatment work? In a patient destined to recur, will a treatment change their outcome.” ...

CEL-SCI (CVM) announced that a third-party study published on March 6 in JAMA Oncology provided data that support Multikine’s use as a ...

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of Head and Neck Patients.